Leukocyte glucose index as a novel biomarker for COVID-19 severity

Ramos-Hernández W.M.; Soto L.F.; Del Rosario-Trinidad M.; Farfan-Morales C.N.; De Jesús-González L.A.; Martínez-Mier G.; Osuna-Ramos J.F.; Bastida-González F.; Bernal-Dolores V.; del Ángel R.M.; Reyes-Ruiz J.M. · Scientific Reports (2022) · DOI: 10.1038/s41598-022-18786-5

Resumen

The severity of coronavirus disease 2019 (COVID-19) quickly progresses with unfavorable outcomes due to the host immune response and metabolism alteration. Hence, we hypothesized that leukocyte glucose index (LGI) is a biomarker for severe COVID-19. This study involved 109 patients and the usefulness of LGI was evaluated and compared with other risk factors to predict COVID 19 severity. LGI was identified as an independent risk factor (odds ratio [OR] = 1.727, 95% confidence interval [CI]: 1.026–3.048, P = 0.041), with an area under the curve (AUC) of 0.749 (95% CI: 0.642–0.857, P < 0.0001). Interestingly, LGI was a potential risk factor (OR = 2.694, 95% CI: 1.575–5.283, Pcorrected < 0.05) for severe COVID-19 in female but not in male patients. In addition, LGI proved to be a strong predictor of the severity in patients with diabetes (AUC = 0.915 (95% CI: 0.830–1), sensitivity = 0.833, and specificity = 0.931). The AUC of LGI, together with the respiratory rate (LGI + RR), showed a considerable improvement (AUC = 0.894, 95% CI: 0.835–0.954) compared to the other biochemical and respiratory parameters analyzed. Together, these findings indicate that LGI could potentially be used as a biomarker of severity in COVID-19 patients.

Instituciones: Universidad Nacional Mayor de San Marcos